Characteristics of transplants according to degree of GVHD
| . | GVHD . | P* . | ||
|---|---|---|---|---|
| 0 (n = 8) . | 1-2 (n = 17) . | 3-4 (n = 11) . | ||
| Recipient factor | ||||
| Age, y | 48.0 ± 12.2 | 45.8 ± 13.3 | 44.5 ± 16.2 | .86 |
| Male, % | 87.5 | 58.8 | 72.7 | .38 |
| White, % | 100 | 76.5 | 72.7 | .31 |
| HSCT indication | ||||
| Acute myeloid leukemia | 4 | 5 | 2 | .83† |
| Acute lymphoblastic leukemia | 0 | 3 | 2 | |
| Chronic lymphocytic leukemia | 1 | 0 | 3 | |
| Hodgkin lymphoma | 0 | 3 | 0 | |
| Myelodysplastic syndrome | 1 | 0 | 2 | |
| Aplastic anemia | 1 | 2 | 0 | |
| Other | 1 | 4 | 2 | |
| Conditioning regimen | ||||
| Ablative | 3 | 4 | 4 | .79 |
| Nonablative/reduced intensity | 5 | 13 | 7 | |
| Total body irradiation | 1 | 1 | 2 | |
| Maintenance immunosuppression | ||||
| CellCept | 3 | 14 | 9 | .32 |
| Calcineurin inhibitor | 4 | 3 | 4 | |
| Prednisone | 1 | 3 | 2 | |
| Sirolimus | 0 | 0 | 1 | |
| None | 1 | 0 | 0 | |
| Donor-recipient MHC match | ||||
| 6/6 | 7 | 10 | 5 | .19‡ |
| 2-5/6 | 1 | 6 | 6 | |
| 0/6 | 0 | 1 | 0 | |
| Infection within 100 days of transplant | ||||
| CMV viremia | 2 | 10 | 7 | .50 |
| Bacteremia | 0 | 0 | 1 | |
| . | GVHD . | P* . | ||
|---|---|---|---|---|
| 0 (n = 8) . | 1-2 (n = 17) . | 3-4 (n = 11) . | ||
| Recipient factor | ||||
| Age, y | 48.0 ± 12.2 | 45.8 ± 13.3 | 44.5 ± 16.2 | .86 |
| Male, % | 87.5 | 58.8 | 72.7 | .38 |
| White, % | 100 | 76.5 | 72.7 | .31 |
| HSCT indication | ||||
| Acute myeloid leukemia | 4 | 5 | 2 | .83† |
| Acute lymphoblastic leukemia | 0 | 3 | 2 | |
| Chronic lymphocytic leukemia | 1 | 0 | 3 | |
| Hodgkin lymphoma | 0 | 3 | 0 | |
| Myelodysplastic syndrome | 1 | 0 | 2 | |
| Aplastic anemia | 1 | 2 | 0 | |
| Other | 1 | 4 | 2 | |
| Conditioning regimen | ||||
| Ablative | 3 | 4 | 4 | .79 |
| Nonablative/reduced intensity | 5 | 13 | 7 | |
| Total body irradiation | 1 | 1 | 2 | |
| Maintenance immunosuppression | ||||
| CellCept | 3 | 14 | 9 | .32 |
| Calcineurin inhibitor | 4 | 3 | 4 | |
| Prednisone | 1 | 3 | 2 | |
| Sirolimus | 0 | 0 | 1 | |
| None | 1 | 0 | 0 | |
| Donor-recipient MHC match | ||||
| 6/6 | 7 | 10 | 5 | .19‡ |
| 2-5/6 | 1 | 6 | 6 | |
| 0/6 | 0 | 1 | 0 | |
| Infection within 100 days of transplant | ||||
| CMV viremia | 2 | 10 | 7 | .50 |
| Bacteremia | 0 | 0 | 1 | |